Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's Stake In Essential Health Benefits

This article was originally published in RPM Report

Executive Summary

The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.
Advertisement

Related Content

Health Care Reform's Pricing Impact: 340B Purchasers See Initial 10% Decline in Brand Prices
Health Care Reform: For Biopharmas There Is Much To Like
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
Health Care and the 2008 Election: Revolution, Reform or Return to Business-as-Usual?

Topics

Advertisement
UsernamePublicRestriction

Register

PS080825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel